Back to Newsroom

AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a collaboration with the Western Sydney Local Health District and the Westmead Institute for Medical Research, based in Sydney, Australia. The agreement covers compassionate use treatment of patients with severe Staphylococcus aureus and Pseudomonas aeruginosa infections with AmpliPhi’s investigational bacteriophage therapeutics AB-SA01 and AB-PA01.
READ MORE…